Sun Wei, Hesse Shayla, Xu Miao, Childs Richard W, Zheng Wei, Williamson Peter R
National Center for Advancing Translational Sciences, Bethesda, MD, United States.
Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, United States.
Front Med (Lausanne). 2018 Sep 20;5:267. doi: 10.3389/fmed.2018.00267. eCollection 2018.
Antibiotic management of infections with multidrug-resistant organisms (MDRO) represents a complex clinical challenge. We report here the first patient with a severe MDRO infection managed with assistance of a novel "real-time" 3-day high-throughput screen (HTS) that allowed screening of 9 drugs in 14 combinations in 2,304 total samplings. Identified synergies were used to modify patient therapy with the goal of reducing drug-induced toxicity. The desired clinical outcome was achieved on the HTS-informed therapeutic regimen, supporting the utility of HTS technology to expand standard antimicrobial susceptibility testing.
多重耐药菌(MDRO)感染的抗生素管理是一项复杂的临床挑战。我们在此报告首例患有严重MDRO感染的患者,该患者在一种新型“实时”3天高通量筛选(HTS)的辅助下得到治疗,这种筛选能够在总共2304次采样中对9种药物的14种组合进行筛选。所确定的协同作用被用于调整患者的治疗方案,目的是降低药物诱导的毒性。基于HTS信息的治疗方案实现了预期的临床结果,这支持了HTS技术在扩大标准抗菌药敏试验方面的实用性。